Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones May 25, 2023 CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting - Read More December 14, 2022 CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort - Read More November 22, 2022 CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors - Read More Load MoreLoadingMeet us at the following conferences & events ASCO '23 June 2-6, 2023 Chicago, IL, USA Read More BIO '23 June 5-9, 2023 Boston, MA, USA Read More
